Hospira Reports Third-Quarter 20...(perations $161.5 $132.7 2...),Health

Date:10/27/2009

perations $161.5 $132.7 21.7% $207.2 $161.5 28.3% Diluted EPS $0.71 $0.51 39.2% $0.90 $0.63 42.9% Statistics (as a % of Net Sales) ------------------------------- Gross Profit (Net Sales less Cost of Products Sold) 39.3% 36.1% 41.5% 38.4% Income from Operations 16.0% 14.3% 20.6% 17.5%

Results under U.S. Generally Accepted Accounting Principles (GAAP) include items detailed in the schedules attached to this press release.

Net sales increased 8.9 percent to $1.0 billion in the third quarter of 2009, compared to $926 million in the third quarter of 2008. The growth was driven by an increase in Specialty Injectable Pharmaceuticals, primarily a result of the third-quarter launch of oxaliplatin in solution form in the United States.

Adjusted* income from operations increased 28.3 percent to $207 million in the third quarter of 2009, compared to $162 million in the third quarter of 2008. Driving the majority of the increase were higher sales volumes and increased manufacturing efficiency. Partially offsetting these factors was the impact of certain product recall-related costs as well as the impact of foreign exchange.

Cash Flow

Cash flow from operations for the first nine months of 2009 was $541 million, compared to $329 million generated for the same period in 2008.

Capital expenditures decreased to $119 million for the first nine months of 2009, compared to $127 million for the same period in 2008, due to the impact of the company's tighter capital-spending controls implemented in the second half of 2008.

2009 Projections

Hospira continues to expect net sales for the year to increase approximately 5 to 7 percent on a constant-currency basis. Including the impact of foreign exchange, the company expects net sales to be
'/>"/>

SOURCE Hospira, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs